Get the Stockscreener App
2.31
7.44%
0.16
Exicure Inc stock is traded at $2.31, with a volume of 52,950.
It is up +7.44% in the last 24 hours and down -24.51% over the past month.
Exicure Inc is a clinical-stage biotechnology company focused on developing treatments for blood-related diseases, with an emphasis on small-molecule therapies that have the potential to benefit a broad range of patients. The company acquired GPCR Therapeutics USA and secured a license for GPC-100 (Burixafor), a clinical-stage small-molecule compound that inhibits the chemokine receptor CXCR4. GPC-100 has demonstrated the ability to effectively mobilize various cell types, including hematopoietic stem cells and lymphocytes, highlighting its broad therapeutic potential across multiple indications.
See More
Previous Close:
$2.15
Open:
$2.345
24h Volume:
52,950
Relative Volume:
2.71
Market Cap:
$14.72M
Revenue:
$500.00K
Net Income/Loss:
$-9.78M
P/E Ratio:
-1.4982
EPS:
-1.5419
Net Cash Flow:
$-8.10M
1W Performance:
-18.09%
1M Performance:
-24.51%
6M Performance:
-62.07%
1Y Performance:
-69.69%
1-Day Range:
$2.10
$2.49
1-Week Range:
$1.71
$3.05
52-Week Range:
$1.71
$9.50
Exicure Inc Stock (XCUR) Company Profile
Name
Exicure Inc
Sector
Industry
Phone
847-673-1707
Address
2430 N. HALSTED ST., CHICAGO, IL
Compare XCUR vs MOBBW, SHMD, GOODO, PSNYW, DWLD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
| 0.625 | 0 | 0 | 0 | 0 | 0.00 | |
MOBBW
Mobilicom Limited Warrants
|
2.38 | 3.16B | 0 | 0 | 0 | 0.00 |
SHMD
Schmid Group N V
|
6.54 | 425.01M | 52.15M | -21.46M | 0 | -0.4675 |
GOODO
Gladstone Commercial Corporation
|
20.26 | 372.90M | 0 | 0 | 0 | 0.00 |
PSNYW
Polestar Automotive Holding Uk
|
2.909 | 269.09M | 2.07B | -1.42B | -1.37B | -0.6765 |
DWLD
Davis Select Worldwide ETF
|
46.61 | 0 | 0 | 0 | 0 | 0.00 |
Exicure Inc Stock (XCUR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-13-21 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| Dec-18-20 | Initiated | BMO Capital Markets | Outperform |
| Nov-20-19 | Initiated | Guggenheim | Buy |
Exicure Inc Stock (XCUR) Latest News
Exicure StockThursday technicals and trading picture - AD HOC NEWS
Total equity of Exicure, Inc. – DUS:2H0 - TradingView
Exicure, Inc. Balance Sheet – DUS:2H0 - TradingView
Exicure Inc (XCUR) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Exicure Inc (XCUR) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Exicure Inc (XCUR) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Exicure Inc (XCUR) Valuation: PE, PB & Fair Value Analysis - TradingKey
Exicure Inc (XCUR) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Exicure Inc (XCUR) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Exicure Inc (XCUR) Institutional Confidence - TradingKey
Exicure Inc (XCUR) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Exicure Inc. (XCUR) Plunges 22% as Selling Pressure Mounts – Key Support in FocusALMA Signal - newsline.com
XCUR Q2 2022 Earnings: Wider-than-Expected Loss with No Reported RevenueRevenue Warning Signal - newsline.com
XCUR Q2 2022 Earnings: EPS Misses Estimates as Exicure Reports No Revenue and Continues R&D Focus - newsline.com
Exicure Inc. Q2 2022 Earnings: Significant EPS Miss Amidst No RevenueGAAP Earnings Report - newsline.com
Exicure receives Nasdaq notice for falling below $2.5M equity requirement, plans to regain compliance. - Pluang
Exicure receives Nasdaq notice for equity deficiency - Investing.com
Exicure Announces Receipt of Nasdaq Notice Regarding Minimum Stockholders’ Equity Requirement - The Manila Times
Exicure receives Nasdaq notice for equity deficiency By Investing.com - Investing.com Canada
XCUR Q2 2022 Earnings: Wider-Than-Expected Loss on No RevenueAnalyst Drop Coverage - newsline.com
Exicure Inc stock (US30205M1027): biotech penny stock seeks direction after strategic shifts - AD HOC NEWS
XCUR Technical Analysis | Trend, Signals & Chart Patterns | EXICURE INC (NASDAQ:XCUR) - ChartMill
Exicure Regains Nasdaq Compliance After Late Quarterly Filing - The Globe and Mail
Exicure Announces Receipt Of Nasdaq Delinquency Notice And Filing Of Form 10-Q - TradingView
Exicure receives Nasdaq notice for delayed quarterly filing By Investing.com - Investing.com South Africa
Exicure receives Nasdaq notice for delayed quarterly filing - Investing.com
Exicure Announces Receipt of Nasdaq Delinquency Notice and Filing of Form 10-Q - The Manila Times
Exicure faces Nasdaq noncompliance over late 10-Q, then files report - Stock Titan
Exicure receives Nasdaq notice for late 10-Q, files report and says compliance restored - TradingView
Exicure (XCUR) addresses Nasdaq delinquency after delayed Q1 2026 10-Q filing - Stock Titan
Exicure, Inc. Q1 2026 Financials: Strategic Alternatives, Going Concern Doubts, and Zero Revenue Reported - Minichart
XCUR Q2 2022 Earnings: EPS Misses Estimates Amid Operational ChallengesProfit Margin Analysis - The Legal Advocate
Exicure Q2 2022 Earnings: EPS Misses Estimates as Pre-Revenue Biotech Continues DevelopmentEarnings Outlook Update - The Legal Advocate
Exicure, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Exicure (NASDAQ: XCUR) posts Q1 2026 loss and flags going concern, Nasdaq risks - Stock Titan
Exicure Deadline Alert - TMX Newsfile
XCUR Q2 2022 Earnings: EPS Misses Estimates as Clinical-Stage Biotech Reports No RevenueFinancial Health Score - newsline.com
Exicure Inc. (XCUR) Q2 2022 Earnings: Wider-than-Expected Loss, No Revenue, Shares Edge Higher - The Legal Advocate
Exicure (XCUR) Q2 2022 Earnings: Wider-Than-Expected Loss Fails to Deter InvestorsStock Idea Network - Newser
Exicure Inc. (XCUR) Slips 3.6% as Shares Test Support Near $2.53Stock Idea Hub - Newser
XCUR Q2 2022 Earnings: Wider-than-Expected Loss Highlights Challenges for Pre-Revenue Biotech - Newser
Exicure Inc stock (US30205M1027): micro-cap biotech restructures after Nasdaq delisting - AD HOC NEWS
Exicure delays quarterly filing, trims quarterly loss - TipRanks
Exicure (XCUR) delays Q1 2026 10-Q; prelim net loss $1.83M - Stock Titan
Exicure stock (US30205M1027): Filing highlights ongoing biotech focus - AD HOC NEWS
TradingKey - TradingKey
XCUR (Exicure) shares decline 3% after EPS miss of 35.6%, raising concerns over biotech's cash burn and growth prospects.Trending Social Stocks - Newser
The biggest catalyst for Exicure (XCUR) nobody is watching (-1.82%) 2026-05-11Open Trading Community - Newser
Number of shareholders of Exicure, Inc. – SWB:2H0 - TradingView
Exicure Shareholder Alert - TMX Newsfile
What Exicure (XCUR) does that its rivals cannot (+2.12%) 2026-05-08Investment Community Signals - newser.com
Exicure Inc Stock (XCUR) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.74%
1.44%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):